Biocartis associates with AstraZeneca on lung cancer diagnostics

Published On 2018-11-30 03:45 GMT   |   Update On 2018-11-30 03:45 GMT

Belgium: Belgian molecular diagnostics company Biocartis Group said on Thursday it had entered into an agreement with British drugmaker AstraZeneca to obtain faster lung cancer molecular diagnostic biomarker results in Europe.


Following the agreement, a prospective lung cancer study with Biocartis's Idylla EGFR Mutation Test will be conducted in Belgium, France, Germany and Italy.


"We are very excited to be collaborating with AstraZeneca in the area of lung cancer ... For Biocartis, this is yet another important collaboration to support the further roll-out of our Idylla platform," Biocartis Chief Executive Officer Herman Verrelst said.


The study is aimed at determining how the Idylla platform's features can speed up and simplify lung cancer diagnostics by delivering biomarker results faster.


Also Read: AstraZeneca sells infant drug rights to Sobi for $1.5 bln upfront
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News